Stock listing

NASDAQ:ANTX AN2 Therapeutics, Inc. Stock

Home listing (NASDAQ) of AN2 Therapeutics, Inc.

Follow AN2 Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ANTX

$5.08 USD +0.13 (+2.6%)

Close on Nov 20, 2026

Past year +370.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.99 – $5.49 USDNov 20, 2026
Volume
332,710 sharesNov 20, 2026
Market cap
$192.8M USDAt the close on Nov 20, 2026 · price × 37.94M shares outstanding
52-week range
$1.00 – $7.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.33M USDMedian day 240,355 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
AN2 Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ANTX · Home$5.08 USD+0.13 (+2.6%)332,710$5.13$5.49$4.99$4.95Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ANTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$5.08+0.13+2.6%$5.13$5.49$4.99332,710
$4.95+0.72+17.0%$4.40$5.32$4.23967,421
$4.23-0.24-5.4%$4.50$4.60$3.915285,651
$4.47-0.08-1.8%$4.51$4.70$4.365246,860
$4.55+0.11+2.5%$4.42$4.58$4.25205,686
$4.44-0.02-0.4%$4.48$4.75$4.34186,344
$4.46+0.13+3.0%$4.40$4.747$4.277197,630
$4.33+0.33+8.3%$3.99$4.505$3.93271,603
$4.000.000.0%$4.06$4.13$3.97496,679
$4.00+0.045+1.1%$3.99$4.11$3.90240,355
$3.955-0.295-6.9%$4.22$4.255$3.82152,967
$4.25+0.07+1.7%$4.22$4.31$4.10131,826
$4.18-0.17-3.9%$4.38$4.55$4.10160,400
$4.35-0.18-4.0%$4.54$4.64$4.241299,604
$4.53-0.16-3.4%$4.66$4.76$4.31284,722
$4.69+0.17+3.8%$4.57$4.90$4.53555,792
$4.52+0.66+17.1%$3.86$4.60$3.85545,417
$3.86+0.23+6.3%$3.61$3.89$3.54239,623
$3.63+0.08+2.3%$3.55$3.70$3.50196,183
$3.55-0.09-2.5%$3.61$3.66$3.47124,439
$3.64+0.04+1.1%$3.57$3.72$3.52195,191
$3.60+0.04+1.1%$3.58$3.78$3.57177,367
$3.56+0.19+5.6%$3.38$3.59$3.36129,744
$3.37-0.01-0.3%$3.39$3.46$3.21330,870
$3.38-0.22-6.1%$3.60$3.62$3.30281,730
$3.60+0.06+1.7%$3.50$3.69$3.50295,943
$3.54-0.06-1.7%$3.55$3.73$3.33431,025
$3.60-0.70-16.3%$4.30$4.32$3.59515,050
$4.30-0.10-2.3%$4.41$4.41$4.24298,465
$4.40-0.28-6.0%$4.65$4.67$4.26442,134
$4.68-0.17-3.5%$4.77$4.86$4.43427,826
$4.85-0.22-4.3%$5.02$5.06$4.695365,253
$5.07-0.54-9.6%$5.39$5.60$5.005318,215
$5.61-0.10-1.8%$5.69$5.86$5.50299,949
$5.71+0.09+1.6%$5.64$5.99$5.51451,333
$5.62+0.30+5.6%$5.29$5.73$5.155509,439
$5.32+0.23+4.5%$5.07$5.35$5.00199,204
$5.09+0.08+1.6%$4.99$5.20$4.76178,839
$5.01+0.13+2.7%$4.89$5.17$4.67318,456
$4.88-0.01-0.2%$4.91$4.95$4.71155,127
$4.89+0.06+1.2%$4.77$5.06$4.72258,937
$4.830.000.0%$4.86$4.95$4.67306,158
$4.83-0.13-2.6%$5.00$5.05$4.70191,680
$4.96-0.09-1.8%$5.06$5.25$4.92305,221
$5.05+0.15+3.1%$4.89$5.15$4.80670,954
$4.90-0.44-8.2%$5.39$5.47$4.88204,494
$5.34-0.02-0.4%$5.38$5.44$5.295146,046
$5.36-0.10-1.8%$5.43$5.50$5.20156,797
$5.46+0.05+0.9%$5.43$5.645$5.34221,486
$5.41-0.28-4.9%$5.70$5.78$5.40103,538
$5.69-0.04-0.7%$5.56$5.88$5.54222,312
$5.73-0.25-4.2%$5.98$6.125$5.605175,804
$5.98+0.09+1.5%$6.00$6.06$5.76335,287
$5.89-0.06-1.0%$5.97$6.06$5.8577,182
$5.950.000.0%$6.05$6.20$5.79199,660
$5.95+0.47+8.6%$5.46$6.00$5.46353,561
$5.48-0.07-1.3%$5.53$5.67$5.40215,423
$5.55-0.03-0.5%$5.58$5.645$5.40124,021
$5.58-0.16-2.8%$5.67$5.78$5.40240,866
$5.74+0.21+3.8%$5.46$5.79$5.46204,041
$5.53-0.13-2.3%$5.66$5.85$5.50287,524
$5.66+0.03+0.5%$5.67$5.80$5.60217,706
$5.63-0.18-3.1%$5.82$5.82$5.59171,420
$5.81+0.02+0.3%$5.84$5.89$5.50225,449
$5.79-0.17-2.9%$5.98$6.13$5.72195,335
Ticker
NASDAQ:ANTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All AN2 Therapeutics, Inc. news

AN2 Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 62 in all · newest Nov 20, 2026 · oldest 2022
Decks
3 decks · latest September 2026

Where AN2 Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ANTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ANTXBOATSUnited StatesUSD

Valuation

Price/book 2.5× against a median of 2.7×: 4th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$128.4M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.54

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
AN2 Therapeutics, Inc. · NASDAQ:ANTXUS$192.8MUS$128.4Mn/an/an/a2.5×n/a0.0×0.54
Bright Minds Biosciences Inc. · CSE:DRUGUS$199.5M−US$15.18Mn/an/an/a0.9×n/a0.0×0.32
Newron Pharmaceuticals S.p.A. · SIX:NWRNUS$199.5MUS$206.2Mn/a9.8×n/an/a−69.2%n/an/a
NervGen Pharma Corp. · NASDAQ:NGENUS$198.4MUS$137.8Mn/an/an/a16.4×n/a0.0×1.46
BioAge Labs, Inc. · NASDAQ:BIOAUS$196.4M−US$87.20Mn/a−10.1×n/a0.6×n/a0.0×2.06
Lineage Cell Therapeutics, Inc. · AMEX:LCTXUS$195.3MUS$152.1M111×14.0×n/a2.9×16.2%0.0×1.33
AC Immune SA · NASDAQ:ACIUUS$193.9MUS$110.5Mn/a4.7×n/a6.0×−181.9%0.1×1.56
SillaJen, Inc. · KRX:215600US$193.5MUS$141.7Mn/a17.6×n/a2.6×−223.8%0.0×n/a
Cartesian Therapeutics, Inc. · NASDAQ:RNACUS$187.3MUS$114.5Mn/a112×n/an/an/an/a1.23
Artiva Biotherapeutics, Inc. · NASDAQ:ARTVUS$186.9M−US$123.1Mn/an/an/a0.6×n/a0.0×1.34
Inventage Lab, Inc. · KRX:389470US$185.9MUS$113.3Mn/a61.3×n/a2.8×−127.0%0.2×n/a
Median of the othersUS$194.6MUS$113.9M111×14.0×2.7×−127.0%0.0×1.34

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
9.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.81 · 1 analyst

Team and board

Officers

OfficerRole
Eric EasomCo-founder, President, CEO, and Chair
Maggie FitzPatrickFitzpatrick & Co, Founder & CEO, Lead Independent Director
Lucy O. DayChief Financial Officer
Lynn MarksSenior Vice President (Retired), GlaxoSmithKline
Cameron TrenorChief Medical Officer
Joseph S. ZakrzewskiCo-Founder
Rob ReadnourManaging Director, Mountain Group Partners, Director

Board

DirectorRole
Eric EasomCo-founder, President, CEO, and Chair
Joseph S. ZakrzewskiCo-Founder
Kabeer AzizPrincipal, Adjuvant Capital
Lynn MarksSenior Vice President (Retired), GlaxoSmithKline
Maggie FitzPatrickFitzpatrick & Co, Founder & CEO, Lead Independent Director
Melvin SpigelmanGATB
Patricia MartinDirector
Stephanie WongDirector

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open0.0%
Q2 2026Aug 11, 2026 · After close+7.0%
Q1 2026May 11, 2026 · After close−9.5%
Q4 2025Mar 18, 2026−21.8%
Q3 2025Nov 12, 2025 · After close−4.2%
Q2 2025Aug 14, 2025 · After close+1.4%
Q1 2025May 13, 2025 · After close+0.8%
Q4 2024Mar 25, 2025+0.7%
Q3 2024Nov 13, 2024 · After close−1.0%
Q2 2024Aug 13, 2024 · After close−3.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close−1.7%
Q4 2023Mar 28, 2024 · After close+15.7%
Q3 2023Nov 9, 2023 · After close−7.1%
Q2 2023Aug 10, 2023 · After close+0.4%
Q1 2023May 11, 2023 · After close+0.6%
Q4 2022Mar 29, 2023 · After close−1.9%
Q3 2022Nov 9, 2022 · After close−7.4%
Q2 2022Aug 11, 2022 · After close+64.7%
Q1 2022May 10, 2022 · After close+6.8%
Q4 2021Mar 28, 2022 · After close−2.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck50 slidesSeptember 2026
Corporate Update (March 2026)Corporate update17 slidesMar 4, 2026
Investor Presentation (June 2025)Investor deck40 slidesJun 11, 2025

Open Decks

IPO

Priced at US$15.00 a share on Mar 24, 2022.

Price
US$15.00 a share
Shares offered
4,600,000 shares of common stock
Offering size
US$69 million
Underwriters' option
Up to 690,000 more shares
Underwriters
Cowen, SVB Leerink, Evercore ISI, Oppenheimer & Co. · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceSep 24, 2021
Filed publiclyMar 4, 2022
Amended onceMar 21, 2022
Shares registered with an exchangeMar 22, 2022
Declared effective by the SECMar 24, 2022
Final prospectus, with the priceMar 28, 2022

Open IPO · From the cover of the final prospectus (424B4) filed Mar 28, 2022

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue000000
Cost of revenue77.0K
Gross profit-77.0K
Research and development24.8M40.5M54.9M28.5M16.2M6.02M29.3M
Selling, general and administrative13.3M14.1M14.8M12.8M4.67M1.26M1.73M
Operating income-38.1M-56.8M-69.6M-42.3M-21.6M-7.28M-31.1M
Depreciation and amortization54.6M69.6M692.0K100.0K7.28M31.1M
EBITDA-2.23M0-41.6M-21.5M00
Interest expense514.0K69.0K3.00K0
Income before tax-35.2M-51.3M-64.7M-41.0M-21.5M-13.6M-33.8M
Income tax00000-3.00K-31.1K
Net income-35.2M-51.3M-64.7M-41.0M-21.5M-13.6M-33.8M
Earnings per share, basic-1.16-1.72-2.74-2.79-10.64-0.73-1.80
Earnings per share, diluted-1.16-1.72-2.74-2.79-10.64

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents19.9M21.4M15.6M27.2M12.1M4.07M5.60M
Short-term investments38.1M62.3M91.6M68.8M46.5M0
Receivables900.0K300.0K1.40M
Current assets59.9M86.3M110.5M98.6M60.1M4.23M5.70M
Total assets62.0M92.1M138.7M102.6M65.3M4.23M5.70M
Accounts payable3.02M3.32M2.68M2.12M1.06M132.0K51.0K
Current liabilities8.72M10.2M14.0M7.19M3.40M1.46M159.0K
Total debt53.0K728.0K
Total liabilities8.89M10.2M14.0M7.19M3.41M1.48M887.0K
Shareholders' equity53.1M81.8M124.7M95.4M-47.4M2.75M4.81M
Shares outstanding27.4M29.9M29.7M19.4M2.73M18.7M18.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-29.8M-49.3M-53.3M-33.5M-20.5M-5.36M-2.49M
Capital spending0000000
Free cash flow-29.8M-49.3M-53.3M-33.5M-20.5M-5.36M-2.49M
Cash from investing28.3M54.6M-43.3M-21.8M-50.0M-50.0M-50.0M
Cash from financing113.0K372.0K85.0M70.4M78.5M3.84M8.08M
Dividends paid-1.82M
Share buybacks-11.0K
Change in cash-1.41M5.70M-11.6M15.1M8.03M-1.53M5.60M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
S-8 · Registration statement for employee plansSep 14, 2026Offer documentSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 27, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
8-K · Current reportJun 8, 2026Meeting outcomeSEC
8-K · Current reportJun 4, 2026Current reportSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
ARS · Annual report to shareholdersApr 22, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 21, 2026Other filingsSEC
424B3 · ProspectusApr 20, 2026Offer documentSEC
424B5 · ProspectusApr 20, 2026Offer documentSEC
CORRESP · Letter to the SECApr 16, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 15, 2026Other filingsSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
S-3 · Registration statementApr 9, 2026Offer documentSEC
8-K · Current reportApr 9, 2026Current reportSEC
DMar 25, 2026Other filingsSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
8-K · Current reportMar 20, 2026Management or board changeSEC
S-8 · Registration statement for employee plansMar 17, 2026Offer documentSEC
10-K · Annual reportMar 17, 2026Annual reportSEC
8-K · Current reportMar 17, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMar 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMar 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMar 13, 2026Big-stake noticeSEC
8-K · Current reportMar 9, 2026Material contractSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
8-K · Current reportJan 29, 2026Management or board changeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025Current reportSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
8-K · Current reportJun 20, 2025FinancingSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 18, 2025Big-stake noticeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 4, 2025Big-stake noticeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 30, 2025Big-stake noticeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
8-K · Current reportMay 27, 2025Meeting outcomeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025Current reportSEC
SCHEDULE 13D · Big-stake noticeMay 7, 2025Big-stake noticeSEC
8-K · Current reportMay 1, 2025Current reportSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 10, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 25, 2025Offer documentSEC
10-K · Annual reportMar 25, 2025Annual reportSEC
8-K · Current reportMar 25, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 28, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2024Insider tradeSEC
8-K · Current reportNov 5, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedAug 28, 2024Big-stake noticeSEC
8-A12B · Registration of shares for listing on an exchangeAug 19, 2024Other filingsSEC
8-K · Current reportAug 19, 2024Material contractSEC
144 · Notice of proposed saleAug 15, 2024Other filingsSEC
144 · Notice of proposed saleAug 15, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedAug 14, 2024Big-stake noticeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedAug 13, 2024Big-stake noticeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
SC 13G · Big-stake noticeAug 12, 2024Big-stake noticeSEC
8-K · Current reportAug 8, 2024Management or board changeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
SC 13G · Big-stake noticeJul 3, 2024Big-stake noticeSEC
8-K · Current reportJun 24, 2024Meeting outcomeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
10-K/A · Annual report, amendedMay 14, 2024Annual reportSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC

This page holds 200 of 390 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from AN2 Therapeutics, Inc.’s releases · as of Nov 5, 2026

Common shares
37,943,650
Fully diluted
37,943,650

Fully diluted

LineSharesAs of
Common shares37,943,650Nov 5, 2026

Share count over time

CountShares
Nov 5, 202637,943,650

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vivo Capital, LLC3.15M8.3%US$16.8MSep 30, 2026
Commodore Capital LP2.93M7.7%US$15.6MSep 30, 2026
Millennium2.48M6.5%US$13.2MSep 30, 2026
BlackRock1.77M4.7%US$9.42MSep 30, 2026
Spruce Street Capital LP1.75M4.6%US$9.32MSep 30, 2026
Vanguard1.63M4.3%US$8.67MSep 30, 2026
Acorn Capital Advisors, LLC1.3M3.4%US$6.92MSep 30, 2026
Adage Capital Partners Gp, L.L.C.1M2.6%US$5.32MSep 30, 2026
Citadel984K2.6%US$5.24MSep 30, 2026
Boxer Capital Management, LLC944K2.5%US$5.02MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Geode Capital684K1.8%US$3.64MSep 30, 2026
Goldman Sachs635K1.7%US$3.38MSep 30, 2026
Tetragon Partners GP Ltd603K1.6%US$3.21MSep 30, 2026
SummitTX Capital, L.P.598K1.6%US$3.18MSep 30, 2026
Sio Capital Management, LLC548K1.4%US$2.92MSep 30, 2026
Ameriprise537K1.4%US$2.86MSep 30, 2026
Ally Bridge Group (NY) LLC526K1.4%US$2.8MSep 30, 2026
Woodline Partners LP447K1.2%US$2.38MSep 30, 2026
State Street444K1.2%US$2.36MSep 30, 2026
Stonepine Capital Management, LLC351K0.92%US$1.87MSep 30, 2026
Prosight Management, LP351K0.92%US$1.87MSep 30, 2026
Almitas Capital LLC349K0.92%US$1.86MSep 30, 2026
Balyasny Asset Management L.P.287K0.76%US$1.53MSep 30, 2026
BNP Paribas256K0.67%US$1.36MSep 30, 2026
Seven Fleet Capital Management LP254K0.67%US$1.35MSep 30, 2026
UBS252K0.66%US$1.34MSep 30, 2026
Russell Investments Group, Ltd.222K0.59%US$1.18MSep 30, 2026
Northern Trust210K0.55%US$1.12MSep 30, 2026
Acuta Capital Partners, LLC142K0.37%US$756KSep 30, 2026
Marshall Wace, LLP106K0.28%US$565KSep 30, 2026
Morgan Stanley81,6310.22%US$434KSep 30, 2026
Renaissance Technologies80,1000.21%US$426KSep 30, 2026
TD78,0250.21%US$415KSep 30, 2026
Dimensional76,0450.20%US$405KSep 30, 2026
BNY67,8650.18%US$361KSep 30, 2026
Schwab64,2200.17%US$342KSep 30, 2026
Bridgeway Capital Management, LLC60,9090.16%US$324KSep 30, 2026
ADAR1 Capital Management, LLC58,8080.15%US$313KSep 30, 2026
Empowered Funds, LLC58,0090.15%US$309KSep 30, 2026
Captrust Financial Advisors41,2970.11%US$220KSep 30, 2026
Bank of America40,3170.11%US$214KSep 30, 2026
Velan Capital Investment Management LP40,0000.11%US$213KSep 30, 2026
Walleye Capital LLC39,9720.11%US$213KSep 30, 2026
Nuveen35,4230.09%US$188KSep 30, 2026
Rhumbline Advisers32,9750.09%US$175KSep 30, 2026
American Century25,6960.07%US$137KSep 30, 2026
DWS22,4950.06%US$120KSep 30, 2026
T. Rowe Price22,0220.06%US$118KSep 30, 2026
Quadrature Capital Ltd20,7350.05%US$110KSep 30, 2026
Gsa Capital Partners LLP20,6030.05%US$110KSep 30, 2026

This page holds 50 of 84 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund853K2.2%US$4.13MJun 30, 2026
iShares Russell 2000 ETF603K1.6%US$2.92MJun 30, 2026
Vanguard Extended Market Index Fund360K0.95%US$1.74MJun 30, 2026
Fidelity Small Cap Index Fund289K0.76%US$1.55MJul 31, 2026
iShares Russell 2000 Value ETF195K0.52%US$946KJun 30, 2026
Fidelity Extended Market Index Fund123K0.32%US$532KMay 31, 2026
iShares Micro-Cap ETF88,8500.23%US$430KJun 30, 2026
Schwab Small-Cap Index Fund64,2200.17%US$344KJul 31, 2026
Ultra-Small Company Market Fund59,0000.16%US$286KJun 30, 2026
Master Small Cap Index Series49,4700.13%US$239KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Total Market Index Fund48,5040.13%US$210KMay 31, 2026
Nuveen Small Cap Blend Index Fund35,3330.09%US$189KJul 31, 2026
Dimensional U.S. Small Cap ETF35,2940.09%US$189KJul 31, 2026
Fidelity Series Total Market Index Fund34,9640.09%US$151KMay 31, 2026
Fidelity Small Cap Value Index Fund32,9070.09%US$159KJun 30, 2026
U.S. Small Cap Equity Fund29,7170.08%US$159KJul 31, 2026
iShares Russell 2000 Growth ETF29,6250.08%US$143KJun 30, 2026
EQ/2000 Managed Volatility Portfolio27,5140.07%US$133KJun 30, 2026
LVIP State Street Small-Cap Index Fund20,3000.05%US$98,252Jun 30, 2026
Fidelity Nasdaq Composite Index Fund19,6330.05%US$85,011May 31, 2026
U.S. Micro Cap Portfolio15,4480.04%US$82,647Jul 31, 2026
Small Cap Index Fund13,7260.04%US$66,434Jun 30, 2026
Vanguard Balanced Index Fund12,7930.03%US$61,918Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund12,7810.03%US$61,860Jun 30, 2026
Global X Russell 2000 ETF12,6560.03%US$67,710Jul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio10,6000.03%US$51,304Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund8,0430.02%US$43,030Jul 31, 2026
Small-Cap Index Portfolio7,3330.02%US$35,492Jun 30, 2026
U.S. Small Cap Portfolio6,1930.02%US$33,133Jul 31, 2026
1290 VT Micro Cap Portfolio5,9620.02%US$28,856Jun 30, 2026
NVIT Small Cap Index Fund5,8310.02%US$28,222Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio5,8030.02%US$28,087Jun 30, 2026
DWS Small Cap Index VIP4,1470.01%US$20,071Jun 30, 2026
T. Rowe Price Small-Cap Index Fund4,0370.01%US$19,539Jun 30, 2026
BlackRock Small Cap Index V.I. Fund3,536<0.01%US$17,114Jun 30, 2026
1290 VT Small Cap Value Portfolio3,466<0.01%US$16,775Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF3,416<0.01%US$18,276Jul 31, 2026
SA Small Cap Index Portfolio3,099<0.01%US$16,580Jul 31, 2026
Victory Extended Market Index Fund3,042<0.01%US$16,275Jul 31, 2026
Fidelity Small Cap Growth Index Fund2,862<0.01%US$13,852Jun 30, 2026
EQ/Small Company Index Portfolio2,600<0.01%US$12,584Jun 30, 2026
EQ/AB Small Cap Growth Portfolio2,600<0.01%US$12,584Jun 30, 2026
CVT Russell 2000 Small Cap Index Portfolio2,402<0.01%US$11,626Jun 30, 2026
Nationwide Small Cap Index Fund2,314<0.01%US$12,380Jul 31, 2026
Venerable Small Cap Index Fund2,112<0.01%US$10,222Jun 30, 2026
SmallCap Value Fund II1,911<0.01%US$10,224Jul 31, 2026
EQ/Franklin Small Cap Value Managed Volatility Portfolio1,096<0.01%US$5,305Jun 30, 2026
PD Small-Cap Value Index Portfolio986<0.01%US$4,772Jun 30, 2026
Penn Series Small Cap Index Fund800<0.01%US$3,872Jun 30, 2026
Total Stock Market Index Trust669<0.01%US$3,238Jun 30, 2026

This page holds 50 of 62 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Eizen Joshua M
Officer: See Remarks
Sale2,826USD 4.22US$11,926Nov 5, 2026
Readnour Robin Shane
Director
Sale523USD 6.02US$3,148Sep 9, 2026
Readnour Robin Shane
Director
Sale585USD 6.02US$3,522Sep 9, 2026
Readnour Robin Shane
Director
Sale4,725USD 6.02US$28,444Sep 8, 2026
Readnour Robin Shane
Director
Sale5,294USD 6.02US$31,870Sep 8, 2026
Readnour Robin Shane
Director
Sale2,877USD 6.07US$17,463Sep 3, 2026
Readnour Robin Shane
Director
Sale3,223USD 6.07US$19,564Sep 3, 2026
Williams Sarah Joanne
Officer: Principal Accounting Officer
Sale272USD 5.53US$1,504Sep 1, 2026
FitzPatrick Margaret M
Director
Buy2,098USD 5.53US$11,602Sep 1, 2026
Readnour Robin Shane
Director
Sale16,696USD 6.01US$100KAug 17, 2026
All 13 trades
TradeTradeSharesPriceValueDate
Readnour Robin Shane
Director
Sale18,706USD 6.01US$112KAug 17, 2026
Eizen Joshua M
Officer: See Remarks
Sale5,945USD 4.17US$24,791Jul 8, 2026
Williams Sarah Joanne
Officer: Principal Accounting Officer
Sale265USD 4.43US$1,174May 29, 2026

Big stakes

StakeStakeSharesDateFiling
Coastlands Capital LP9.99%3.8MSep 30, 2026Schedule 13G
Commodore Capital LP9.90%3.88MSep 30, 2026Schedule 13G
Vivo Opportunity Fund Holdings, L.P.8.00%2.86MMar 10, 2026Schedule 13G
Adjuvant Capital GP, L.P.7.90%2.37MDec 31, 2024Schedule 13G
Millennium Management LLC6.30%2.24MMar 6, 2026Schedule 13G
Eric Easom6.20%2.41MSep 30, 2026Schedule 13G
BML Investment Partners, L.P.1.40%427KJun 17, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Melvin Spigelman
Other companies: Synergy Pharmaceuticals Inc (Director · Aug 3, 2011 – Aug 15, 2018 · Past); The Medicines Company (Director · May 25, 2006 – May 25, 2018 · Past)
GATB · Since at least Mar 24, 2022
Margaret M FitzPatrick
Other companies: Vistagen Therapeutics, Inc. (Director · Since at least Jul 21, 2021)
Director · Since at least May 5, 2022
Michael Adrian Nazak
Other companies: Aridis Pharmaceuticals Inc. (Chief Financial Officer · Feb 18, 2021 – Feb 18, 2021 · Past)
Chief Accounting Officer · Mar 24, 2022 – Feb 15, 2023 · Past
Patricia Martin
Other companies: Cypherpunk Technologies Inc. (Director · Since at least Jan 17, 2023)
Director · Since at least May 12, 2022
Cameron C Trenor IIIChief Medical Officer · Since at least Aug 24, 2026
Cameron TrenorChief Medical Officer · Since at least Aug 24, 2026
Eric EasomCo-founder, President, CEO, and Chair · Since at least Oct 20, 2026
Gilbert Lynn MarksDirector · Since at least Mar 24, 2022
Joseph S. ZakrzewskiDirector · Since at least Aug 14, 2026
Joshua M EizenSee Remarks · Since at least Jul 8, 2026
All 20 people
PersonSeat
Kabeer AzizDirector · Since at least Mar 24, 2022
Lucy O. DayChief Financial Officer · Since at least Mar 24, 2022
Lynn MarksSenior Vice President (Retired), GlaxoSmithKline · Since at least Nov 5, 2026
Maggie FitzPatrickFitzpatrick & Co, Founder & CEO, Lead Independent Director · Since at least Sep 2, 2026
Paul EckburgChief Medical Officer · Mar 24, 2022 – Mar 15, 2024 · Past
Robin Shane ReadnourDirector · Since at least Mar 24, 2022
Rob ReadnourManaging Director, Mountain Group Partners, Director · Since at least Nov 4, 2026
Sanjay ChandaChief Development Officer · Since at least Mar 24, 2022
Sarah Joanne WilliamsPrincipal Accounting Officer · Since at least Jan 26, 2026
Stephanie WongDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about AN2 Therapeutics, Inc.